#Cytomegalovirus #CMV #Hearing #Neurodevelopment #Prevention #Pediatrics
Postnatal infection with
cytomegalovirus (CMV) is a common viral disease
that primarily affects
infants, particularly in regions with a high prevalence
of the virus. Generally considered
benign in full-term, healthy newborns, the
impact of postnatal CMV on auditory and neurological development remains
uncertain.
The main challenge associated with this infection lies in its
insufficient diagnosis and follow-up. Current neonatal screening programs focus
on the c
ongenital form of the infection, neglecting infants infected after
birth. This lack of follow-up
limits the understanding of long-term
consequences and complicates the identification of children at risk for sensory
or cognitive disorders.
Recent advances in molecular screening techniques allow easier
identification of postnatal infection. When combined with early
hearing
screening programs, they open new perspectives for managing CMV-exposed
infants. However, the link between postnatal infection and potential
alterations in brain or auditory development remains controversial.
This study explores the
impact of postnatal CMV on hearing and
neurological development in infants aged 3 to 10 months. By comparing children
infected after birth with non-infected infants, it aims to determine whether
early screening and management of this infection could improve care and
follow-up for at-risk populations.
Postnatal CMV: A Silent Threat to Infant Hearing?
A subgroup of
438 full-term infants was selected:
- 219 tested
negative for CMV at birth but had a confirmed postnatal infection at 3
months of age,
- 219 remained
negative and served as the control group.
CMV diagnosis was established by PCR amplification on saliva samples,
confirmed by urine analysis. Infants were followed until 10 months of age to
assess the effects of infection on hearing and neurodevelopment. Neurological
development was analyzed using the Malawi Developmental Assessment Tool
(MDAT) and the Hammersmith Infant Neurological Examination (HINE).
Auditory assessment relied on otoacoustic emissions (OAE) tests.
Among the 424 infants followed until 10 months,
no significant impact of
postnatal infection on neurodevelopmental outcomes was identified. However,
infected infants showed an
increased risk of abnormal hearing test results
(32.5% vs. 17.9% in the control group), with a relative risk of 1.99. These
results suggest an
association between postnatal CMV infection and
a higher
risk of hearing impairment, although the early-life neurological impact appears
limited.
Read next: CMV vaccine: we're almost there!
Postnatal CMV: Should We Rethink Our Approach?
Postnatal cytomegalovirus is a common infection among infants,
especially in regions where the virus is highly prevalent. Often asymptomatic,
it remains poorly studied, particularly regarding its potential effects on
hearing. Unlike congenital CMV, it is not included in
neonatal screening
programs, making it difficult to identify at-risk children. The lack of early
monitoring limits prevention and management of auditory or neurodevelopmental
disorders that may arise.
This study investigates
the impact of postnatal CMV on hearing and
neurological development in infants aged 3 to 10 months. The results indicate
that while this infection has no significant effect on child development, it is
associated with an
increased risk of hearing impairment, emphasizing the need
for appropriate care.
However, the study has
some limitations, including a follow-up period
that is too short to assess long-term effects on hearing and neurological
development. Additionally, the auditory assessment was limited to otoacoustic
emissions, without more precise tests such as
auditory evoked potentials,
making the evaluation incomplete. These findings highlight the importance of
integrating
CMV screening and hearing tests into pediatric care, particularly
in high-prevalence areas. Prolonged follow-up of infected children would allow
for a more precise identification of risks and the adaptation of management
strategies to reduce associated complications.
